JP2020504157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504157A5 JP2020504157A5 JP2019537845A JP2019537845A JP2020504157A5 JP 2020504157 A5 JP2020504157 A5 JP 2020504157A5 JP 2019537845 A JP2019537845 A JP 2019537845A JP 2019537845 A JP2019537845 A JP 2019537845A JP 2020504157 A5 JP2020504157 A5 JP 2020504157A5
- Authority
- JP
- Japan
- Prior art keywords
- aki
- threshold
- subject
- assay
- persistent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003556 assay Methods 0.000 claims 36
- 201000011040 acute kidney failure Diseases 0.000 claims 34
- 230000002085 persistent effect Effects 0.000 claims 20
- 238000000034 method Methods 0.000 claims 17
- 102000019034 Chemokines Human genes 0.000 claims 13
- 108010012236 Chemokines Proteins 0.000 claims 13
- 210000001124 body fluid Anatomy 0.000 claims 10
- 239000010839 body fluid Substances 0.000 claims 10
- 238000012360 testing method Methods 0.000 claims 9
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 5
- 230000007717 exclusion Effects 0.000 claims 5
- 238000011088 calibration curve Methods 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 238000012959 renal replacement therapy Methods 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 102100023705 C-C motif chemokine 14 Human genes 0.000 claims 2
- 101710112614 C-C motif chemokine 14 Proteins 0.000 claims 2
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 238000010348 incorporation Methods 0.000 claims 2
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 claims 2
- 230000002459 sustained effect Effects 0.000 claims 2
- 102000015833 Cystatin Human genes 0.000 claims 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 102000013519 Lipocalin-2 Human genes 0.000 claims 1
- 108010051335 Lipocalin-2 Proteins 0.000 claims 1
- 102000019210 Metalloproteinase inhibitor 2 Human genes 0.000 claims 1
- 108050006602 Metalloproteinase inhibitor 2 Proteins 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001447 compensatory effect Effects 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 108050004038 cystatin Proteins 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 108091022862 fatty acid binding Proteins 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044473A JP2022091846A (ja) | 2017-01-12 | 2022-03-18 | Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762445692P | 2017-01-12 | 2017-01-12 | |
| US62/445,692 | 2017-01-12 | ||
| PCT/US2018/013561 WO2018132702A1 (en) | 2017-01-12 | 2018-01-12 | Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044473A Division JP2022091846A (ja) | 2017-01-12 | 2022-03-18 | Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504157A JP2020504157A (ja) | 2020-02-06 |
| JP2020504157A5 true JP2020504157A5 (enExample) | 2021-03-18 |
Family
ID=62840533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537845A Pending JP2020504157A (ja) | 2017-01-12 | 2018-01-12 | Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
| JP2022044473A Pending JP2022091846A (ja) | 2017-01-12 | 2022-03-18 | Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044473A Pending JP2022091846A (ja) | 2017-01-12 | 2022-03-18 | Ｃ－ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11353465B2 (enExample) |
| EP (2) | EP3568695A4 (enExample) |
| JP (2) | JP2020504157A (enExample) |
| CN (2) | CN110651187A (enExample) |
| AU (1) | AU2018207151B2 (enExample) |
| CA (1) | CA3049444A1 (enExample) |
| MX (1) | MX2019008260A (enExample) |
| WO (1) | WO2018132702A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019008260A (es) | 2017-01-12 | 2020-01-27 | Astute Medical Inc | Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c. |
| EP3732196A4 (en) | 2017-12-28 | 2022-01-05 | Astute Medical, Inc. | ANTIBODIES AND ASSAYS FOR CCL14 |
| WO2020243011A1 (en) * | 2019-05-24 | 2020-12-03 | Astute Medical, Inc. | Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement |
| WO2021003284A1 (en) * | 2019-07-02 | 2021-01-07 | Astute Medical, Inc | Antibodies and assays for ccl14 |
| CA3202228A1 (en) * | 2020-11-18 | 2022-05-27 | Astute Medical, Inc. | Methods and compositions for treatment of renal injury and renal failure |
| CN113555122B (zh) * | 2021-07-21 | 2024-04-26 | 中南大学湘雅二医院 | 一种重症脓毒症患者一过性和持续性aki的预测模型及其构建方法 |
| US20250298037A1 (en) * | 2022-03-03 | 2025-09-25 | Astute Medical, Inc. | Methods and compositions for assessing and treating persistent acute kidney injury based on c-c motif chemokine ligand 14 measurement |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
| US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
| US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
| JPH05504841A (ja) | 1990-09-14 | 1993-07-22 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途 |
| US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
| FI934437L (fi) | 1991-04-10 | 1993-11-22 | Biosite Diagnostics Inc | Crosstalk-inhibitorer och deras anvaendning |
| EP0579767B1 (en) | 1991-04-11 | 2000-08-23 | Biosite Diagnostics Inc. | Novel conjugates and assays for simultaneous detection of multiple ligands |
| US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
| US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
| US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
| US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
| US6811773B1 (en) * | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
| US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US20030157573A1 (en) | 2002-02-12 | 2003-08-21 | Orna Mor | Use of Axl receptor for diagnosis and treatment of renal disease |
| CA2614935A1 (en) | 2005-07-21 | 2007-02-01 | The Johns Hopkins University | Methods of detecting and treating acute kidney injury |
| US8609812B2 (en) * | 2007-03-26 | 2013-12-17 | Novartis Ag | Use of β-2-microglobulin to assess glomerular alterations and damage in the kidney |
| US20110059537A1 (en) * | 2007-09-20 | 2011-03-10 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
| EP2324354B1 (en) * | 2008-08-29 | 2014-07-16 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| CN102246038B (zh) | 2008-10-21 | 2014-06-18 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| EP2462438A4 (en) | 2009-08-07 | 2013-01-23 | Rules Based Medicine Inc | METHODS AND DEVICES FOR DETECTING REJECTION OF RENAL TRANSPLANT |
| EA201290195A1 (ru) | 2009-11-07 | 2012-12-28 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| EA201290387A1 (ru) * | 2009-12-20 | 2013-02-28 | Астьют Медикал, Инк. | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности |
| US20120156701A1 (en) | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| PT2666872T (pt) | 2010-02-05 | 2016-07-08 | Astute Medical Inc | Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal |
| AU2011269847A1 (en) | 2010-02-26 | 2013-01-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN105137085A (zh) * | 2010-06-23 | 2015-12-09 | 阿斯图特医药公司 | 用于肾损伤和肾衰竭的诊断及预后的方法和组合物 |
| EP2585827A4 (en) | 2010-06-23 | 2013-12-04 | Astute Medical Inc | METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency |
| WO2012136548A1 (en) * | 2011-04-04 | 2012-10-11 | Universiteit Gent | Biomarkers for acute kidney injury |
| WO2013043310A1 (en) | 2011-08-26 | 2013-03-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP2788759B1 (en) | 2011-12-08 | 2019-02-20 | Astute Medical, Inc. | Methods and uses for diagnosis of renal injury and renal failure |
| WO2013096740A1 (en) | 2011-12-21 | 2013-06-27 | Alere San Diego Inc. | Methods and compositions for assigning likelihood of chronic kidney disease progression |
| PT3210018T (pt) | 2014-10-20 | 2021-10-04 | Astute Medical Inc | Métodos e composições para o diagnóstico e prognóstico de lesão renal e insuficiência renal |
| MX2019008260A (es) * | 2017-01-12 | 2020-01-27 | Astute Medical Inc | Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c. |
-
2018
- 2018-01-12 MX MX2019008260A patent/MX2019008260A/es unknown
- 2018-01-12 CN CN201880012782.7A patent/CN110651187A/zh active Pending
- 2018-01-12 EP EP18738815.2A patent/EP3568695A4/en not_active Withdrawn
- 2018-01-12 EP EP22155208.6A patent/EP4063853A1/en not_active Withdrawn
- 2018-01-12 CA CA3049444A patent/CA3049444A1/en active Pending
- 2018-01-12 JP JP2019537845A patent/JP2020504157A/ja active Pending
- 2018-01-12 CN CN202111365747.3A patent/CN114088950A/zh active Pending
- 2018-01-12 AU AU2018207151A patent/AU2018207151B2/en active Active
- 2018-01-12 US US16/475,326 patent/US11353465B2/en active Active
- 2018-01-12 WO PCT/US2018/013561 patent/WO2018132702A1/en not_active Ceased
-
2022
- 2022-03-18 JP JP2022044473A patent/JP2022091846A/ja active Pending
- 2022-05-06 US US17/739,009 patent/US12203944B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504157A5 (enExample) | ||
| WO2010057184A3 (en) | Methods for detection of acute kidney injury in humans | |
| JP2022091846A5 (enExample) | ||
| Bastarache et al. | Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples | |
| NZ619918A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| JP2015517801A5 (enExample) | ||
| JP2022046669A5 (enExample) | ||
| RU2009139295A (ru) | Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек | |
| NZ592552A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| BR112014006741A2 (pt) | método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial | |
| NZ610356A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| Munir et al. | Rapid detection of acute kidney injury by urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass surgery | |
| MY162697A (en) | Methods, devices and kits for detecting or monitoring acute kidney injury | |
| JP2017533427A5 (enExample) | ||
| NZ624614A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| RU2019106324A (ru) | Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии | |
| Florea et al. | Clinical usefulness of HCV core antigen assay for the management of patients with chronic hepatitis C | |
| JP2013510322A5 (enExample) | ||
| JP2015129764A5 (enExample) | ||
| JP2014505254A5 (enExample) | ||
| RU2008103988A (ru) | Способ диагностики рассеяного склероза | |
| JP2013513086A5 (enExample) | ||
| Lidbury et al. | Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis | |
| Kamali et al. | Effects of heparin, citrate, and EDTA on plasma biochemistry of cat: comparison with serum | |
| JP6619611B2 (ja) | バイオマーカー、自己免疫性肝炎の診断補助方法、及び、キット |